Q1 · CROSS-FIELD
Article
Author: Saunier, Sophie ; Porée, Esther ; Delous, Marion ; Krug, Pauline ; Fila, Marc ; Garcia, Hugo ; Salomon, Rémi ; Briseño-Roa, Luis ; Viau, Amandine ; Serafin, Alice S. ; Sin-Monnot, Soraya ; Cagnard, Nicolas ; Lyonnet, Stanislas ; Billot, Katy ; Annereau, Jean-Philippe ; Del Nery, Elaine ; Mahaut, Clémentine ; Benmerah, Alexandre ; Roy, Stéphanie ; Silbermann, Flora ; Garfa-Traore, Meriem ; Birgy, Éléonore ; Antignac, Corinne ; Deleglise, Bérangère ; Rodriguez, Pamela C. ; Jabot-Hanin, Fabienne ; Mehraz, Manon ; Ceccarelli, Salomé ; Furio, Laetitia
Significance
Juvenile nephronophthisis (NPH) is a renal ciliopathy due to a dysfunction of primary cilia for which no curative treatment is available. This paper describes the identification of agonists of prostaglandin E
2
receptors as a potential therapeutic approach for the most common
NPHP1
-associated ciliopathies. We demonstrated that prostaglandin E
1
rescues defective ciliogenesis and ciliary composition in
NPHP1
patient urine-derived renal tubular cells and improves ciliary and kidney phenotypes in our NPH zebrafish and
Nphp1
−/−
mouse models. In addition, Taprenepag alleviates the severe retinopathy observed in
Nphp1
−/−
mice. Finally, transcriptomic analyses pointed out several pathways downstream the prostaglandin receptors as cell cycle progression, extracellular matrix, or actin cytoskeleton organization. Altogether, our findings provide an alternative for treatment of NPH.